 Jonathan Samet
Concepts (994)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Air Pollution | 73 | 2025 | 322 | 11.520 |
Why?
| | Smoking | 107 | 2018 | 1603 | 8.970 |
Why?
| | Air Pollutants | 73 | 2025 | 430 | 7.730 |
Why?
| | Tobacco Smoke Pollution | 52 | 2016 | 256 | 7.390 |
Why?
| | Environmental Exposure | 74 | 2025 | 585 | 7.360 |
Why?
| | Public Health | 54 | 2025 | 587 | 7.130 |
Why?
| | Neoplasms, Radiation-Induced | 33 | 2025 | 103 | 6.070 |
Why?
| | Smoking Prevention | 25 | 2021 | 184 | 5.080 |
Why?
| | Air Pollution, Indoor | 30 | 2024 | 184 | 4.490 |
Why?
| | Lung Neoplasms | 68 | 2026 | 2567 | 4.490 |
Why?
| | Epidemiology | 20 | 2020 | 33 | 4.240 |
Why?
| | Particulate Matter | 37 | 2025 | 330 | 4.210 |
Why?
| | Global Health | 22 | 2020 | 387 | 4.020 |
Why?
| | Smoking Cessation | 26 | 2021 | 440 | 3.630 |
Why?
| | Tobacco Products | 17 | 2024 | 98 | 3.620 |
Why?
| | Tobacco Industry | 19 | 2018 | 61 | 3.520 |
Why?
| | Occupational Exposure | 27 | 2025 | 349 | 3.470 |
Why?
| | Respiratory Tract Diseases | 29 | 2017 | 181 | 3.320 |
Why?
| | Radon | 28 | 2024 | 44 | 3.230 |
Why?
| | Mortality | 31 | 2024 | 359 | 3.090 |
Why?
| | Neoplasms | 34 | 2025 | 2747 | 3.060 |
Why?
| | Environmental Health | 14 | 2021 | 47 | 2.900 |
Why?
| | Occupational Diseases | 19 | 2024 | 162 | 2.780 |
Why?
| | Environmental Monitoring | 28 | 2024 | 371 | 2.560 |
Why?
| | Humans | 443 | 2026 | 141754 | 2.510 |
Why?
| | Uranium | 18 | 2025 | 27 | 2.500 |
Why?
| | Carcinogens | 9 | 2022 | 128 | 2.240 |
Why?
| | Electronic Nicotine Delivery Systems | 15 | 2024 | 105 | 2.230 |
Why?
| | United States | 124 | 2026 | 15310 | 2.100 |
Why?
| | Cardiovascular Diseases | 29 | 2017 | 2096 | 2.010 |
Why?
| | Health Policy | 19 | 2020 | 405 | 2.010 |
Why?
| | Ozone | 11 | 2024 | 133 | 1.900 |
Why?
| | Nuclear Weapons | 2 | 2025 | 7 | 1.840 |
Why?
| | Mining | 18 | 2025 | 33 | 1.830 |
Why?
| | Dronabinol | 3 | 2025 | 244 | 1.670 |
Why?
| | Epidemiologic Methods | 20 | 2012 | 96 | 1.620 |
Why?
| | Risk Assessment | 42 | 2020 | 3508 | 1.530 |
Why?
| | Epidemiologic Studies | 9 | 2024 | 70 | 1.500 |
Why?
| | Research | 13 | 2014 | 455 | 1.450 |
Why?
| | Politics | 7 | 2024 | 102 | 1.440 |
Why?
| | United States Environmental Protection Agency | 10 | 2020 | 28 | 1.430 |
Why?
| | History, 20th Century | 15 | 2025 | 330 | 1.380 |
Why?
| | Research Design | 15 | 2025 | 1146 | 1.370 |
Why?
| | Environmental Policy | 3 | 2020 | 6 | 1.320 |
Why?
| | Tobacco Use Disorder | 8 | 2015 | 245 | 1.320 |
Why?
| | Biomedical Research | 11 | 2020 | 708 | 1.220 |
Why?
| | Respiration Disorders | 7 | 2022 | 79 | 1.210 |
Why?
| | Forecasting | 13 | 2020 | 384 | 1.190 |
Why?
| | Risk Factors | 79 | 2025 | 10482 | 1.160 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 10 | 2025 | 1048 | 1.160 |
Why?
| | Developing Countries | 7 | 2014 | 318 | 1.140 |
Why?
| | Climate Change | 7 | 2023 | 187 | 1.130 |
Why?
| | Ventilation | 4 | 2024 | 44 | 1.120 |
Why?
| | Urban Health | 8 | 2014 | 95 | 1.080 |
Why?
| | Cost of Illness | 5 | 2018 | 313 | 1.080 |
Why?
| | Cannabis | 2 | 2025 | 513 | 1.060 |
Why?
| | Lung Diseases | 12 | 2018 | 793 | 1.040 |
Why?
| | Menthol | 5 | 2021 | 13 | 1.030 |
Why?
| | Nicotine | 18 | 2016 | 350 | 1.020 |
Why?
| | Inhalation Exposure | 7 | 2017 | 108 | 1.020 |
Why?
| | Causality | 8 | 2016 | 131 | 1.020 |
Why?
| | Models, Statistical | 17 | 2016 | 671 | 1.020 |
Why?
| | Nuclear Warfare | 4 | 2024 | 10 | 1.020 |
Why?
| | Cohort Studies | 38 | 2025 | 5815 | 0.980 |
Why?
| | International Agencies | 5 | 2022 | 33 | 0.940 |
Why?
| | Guidelines as Topic | 4 | 2020 | 275 | 0.940 |
Why?
| | Maternal Exposure | 5 | 2016 | 202 | 0.940 |
Why?
| | Cotinine | 10 | 2014 | 78 | 0.940 |
Why?
| | Health Status Disparities | 3 | 2019 | 298 | 0.920 |
Why?
| | History, 21st Century | 8 | 2025 | 220 | 0.900 |
Why?
| | Tuberculosis | 2 | 2019 | 286 | 0.870 |
Why?
| | Cell Phone | 3 | 2014 | 82 | 0.870 |
Why?
| | Particle Size | 19 | 2014 | 404 | 0.870 |
Why?
| | Male | 153 | 2025 | 70179 | 0.860 |
Why?
| | Asbestos | 5 | 2019 | 37 | 0.860 |
Why?
| | Female | 153 | 2025 | 75943 | 0.860 |
Why?
| | Sleep Apnea Syndromes | 6 | 2016 | 90 | 0.850 |
Why?
| | Government Regulation | 5 | 2017 | 51 | 0.850 |
Why?
| | Vaping | 6 | 2024 | 63 | 0.840 |
Why?
| | Environmental Pollutants | 3 | 2019 | 165 | 0.830 |
Why?
| | Cause of Death | 12 | 2016 | 441 | 0.830 |
Why?
| | Adult | 104 | 2025 | 39391 | 0.820 |
Why?
| | Population Health | 1 | 2024 | 48 | 0.820 |
Why?
| | Health Equity | 3 | 2021 | 103 | 0.820 |
Why?
| | Conservation of Natural Resources | 3 | 2020 | 128 | 0.810 |
Why?
| | Aged | 88 | 2025 | 24746 | 0.790 |
Why?
| | Environmental Pollution | 2 | 2020 | 21 | 0.780 |
Why?
| | Public Policy | 11 | 2015 | 82 | 0.780 |
Why?
| | Advisory Committees | 4 | 2020 | 220 | 0.770 |
Why?
| | Urban Population | 12 | 2009 | 485 | 0.770 |
Why?
| | Vehicle Emissions | 7 | 2023 | 65 | 0.760 |
Why?
| | Child Health | 1 | 2024 | 154 | 0.760 |
Why?
| | Flavoring Agents | 3 | 2016 | 13 | 0.750 |
Why?
| | Incidence | 20 | 2024 | 2806 | 0.720 |
Why?
| | Asthma | 14 | 2014 | 1920 | 0.710 |
Why?
| | United States Food and Drug Administration | 5 | 2017 | 212 | 0.710 |
Why?
| | Middle Aged | 97 | 2025 | 34647 | 0.710 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2021 | 19 | 0.700 |
Why?
| | Leadership | 6 | 2024 | 399 | 0.690 |
Why?
| | Brachial Plexus | 1 | 2021 | 33 | 0.690 |
Why?
| | Abnormalities, Radiation-Induced | 1 | 2020 | 1 | 0.680 |
Why?
| | Heart Diseases | 5 | 2013 | 335 | 0.680 |
Why?
| | Public Health Practice | 3 | 2019 | 69 | 0.680 |
Why?
| | Tobacco Smoking | 1 | 2020 | 25 | 0.680 |
Why?
| | Magnetic Resonance Imaging | 8 | 2026 | 3737 | 0.670 |
Why?
| | Anniversaries and Special Events | 1 | 2020 | 17 | 0.670 |
Why?
| | New Mexico | 37 | 2002 | 104 | 0.670 |
Why?
| | Disease | 2 | 2019 | 102 | 0.670 |
Why?
| | Science | 2 | 2022 | 55 | 0.660 |
Why?
| | Social Control, Formal | 1 | 2020 | 12 | 0.640 |
Why?
| | Smokers | 1 | 2020 | 144 | 0.630 |
Why?
| | Smoke | 4 | 2020 | 149 | 0.620 |
Why?
| | Health Care Costs | 3 | 2014 | 427 | 0.610 |
Why?
| | Radiation Exposure | 3 | 2025 | 55 | 0.610 |
Why?
| | Risk | 22 | 2016 | 907 | 0.610 |
Why?
| | Epidemiologists | 1 | 2019 | 5 | 0.610 |
Why?
| | Viruses | 1 | 2021 | 163 | 0.610 |
Why?
| | Research Support as Topic | 6 | 2014 | 121 | 0.600 |
Why?
| | Filtration | 3 | 2017 | 70 | 0.600 |
Why?
| | Carcinogens, Environmental | 4 | 2015 | 14 | 0.600 |
Why?
| | Mexico | 15 | 2019 | 232 | 0.580 |
Why?
| | Morbidity | 7 | 2017 | 322 | 0.570 |
Why?
| | Minority Groups | 4 | 2017 | 278 | 0.570 |
Why?
| | Indians, North American | 14 | 1995 | 655 | 0.560 |
Why?
| | International Cooperation | 10 | 2012 | 203 | 0.560 |
Why?
| | Obesity, Abdominal | 1 | 2018 | 44 | 0.560 |
Why?
| | Chernobyl Nuclear Accident | 1 | 2017 | 5 | 0.550 |
Why?
| | Professional Competence | 4 | 2019 | 97 | 0.550 |
Why?
| | Publications | 2 | 2015 | 51 | 0.550 |
Why?
| | Respiratory Tract Infections | 6 | 2024 | 385 | 0.550 |
Why?
| | Smoke-Free Policy | 2 | 2018 | 13 | 0.550 |
Why?
| | Environmental Illness | 1 | 2017 | 3 | 0.550 |
Why?
| | Proportional Hazards Models | 12 | 2025 | 1268 | 0.550 |
Why?
| | Climate | 5 | 2013 | 89 | 0.530 |
Why?
| | Japan | 6 | 2025 | 133 | 0.530 |
Why?
| | Saliva | 6 | 2014 | 251 | 0.530 |
Why?
| | Cyclonic Storms | 1 | 2018 | 38 | 0.530 |
Why?
| | Age Factors | 20 | 2020 | 3294 | 0.530 |
Why?
| | Biomarkers, Tumor | 4 | 2025 | 1258 | 0.520 |
Why?
| | Air Pollutants, Radioactive | 5 | 2006 | 8 | 0.520 |
Why?
| | Harm Reduction | 4 | 2021 | 39 | 0.510 |
Why?
| | Chronic Disease | 4 | 2015 | 1820 | 0.500 |
Why?
| | Breast Neoplasms | 12 | 2009 | 2257 | 0.500 |
Why?
| | Pandemics | 3 | 2024 | 1656 | 0.500 |
Why?
| | Cities | 6 | 2024 | 134 | 0.500 |
Why?
| | Evidence-Based Practice | 5 | 2018 | 236 | 0.500 |
Why?
| | Perinatal Death | 1 | 2016 | 26 | 0.490 |
Why?
| | Organizational Policy | 2 | 2014 | 84 | 0.490 |
Why?
| | Radiation Injuries | 1 | 2017 | 149 | 0.490 |
Why?
| | Biological Transport, Active | 1 | 2016 | 71 | 0.490 |
Why?
| | Nitrogen Dioxide | 7 | 2023 | 45 | 0.490 |
Why?
| | World Health Organization | 7 | 2016 | 126 | 0.490 |
Why?
| | Prospective Studies | 22 | 2024 | 7777 | 0.490 |
Why?
| | Hospitalization | 9 | 2009 | 2264 | 0.480 |
Why?
| | Prevalence | 18 | 2020 | 2799 | 0.480 |
Why?
| | Stillbirth | 1 | 2016 | 74 | 0.470 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2016 | 36 | 0.470 |
Why?
| | Obesity | 7 | 2018 | 3008 | 0.470 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 289 | 0.470 |
Why?
| | Hazardous Substances | 4 | 2015 | 17 | 0.470 |
Why?
| | Cigarette Smoking | 4 | 2020 | 103 | 0.470 |
Why?
| | Population Surveillance | 10 | 2018 | 482 | 0.460 |
Why?
| | gamma-Glutamyltransferase | 1 | 2015 | 42 | 0.460 |
Why?
| | Tobacco Use | 1 | 2016 | 65 | 0.460 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.460 |
Why?
| | Bone Diseases | 1 | 2016 | 66 | 0.460 |
Why?
| | Coronavirus Infections | 1 | 2020 | 371 | 0.460 |
Why?
| | Organizations | 1 | 2015 | 26 | 0.460 |
Why?
| | Time Factors | 31 | 2019 | 6966 | 0.450 |
Why?
| | Health Services Accessibility | 4 | 2017 | 1027 | 0.450 |
Why?
| | Body Mass Index | 7 | 2016 | 2385 | 0.450 |
Why?
| | Nicotinic Agonists | 3 | 2013 | 136 | 0.450 |
Why?
| | Dose-Response Relationship, Radiation | 5 | 2011 | 144 | 0.450 |
Why?
| | Aged, 80 and over | 24 | 2025 | 7923 | 0.450 |
Why?
| | Republic of Korea | 6 | 2019 | 41 | 0.440 |
Why?
| | Epidemics | 1 | 2016 | 92 | 0.440 |
Why?
| | Soft Tissue Neoplasms | 2 | 2026 | 120 | 0.440 |
Why?
| | Health Facility Administration | 1 | 2014 | 7 | 0.430 |
Why?
| | Social Discrimination | 1 | 2014 | 12 | 0.430 |
Why?
| | Case-Control Studies | 21 | 2016 | 3597 | 0.430 |
Why?
| | Linear Models | 9 | 2018 | 858 | 0.420 |
Why?
| | Alkaloids | 1 | 2014 | 32 | 0.420 |
Why?
| | Odds Ratio | 15 | 2019 | 1057 | 0.410 |
Why?
| | Carbon Monoxide | 5 | 2022 | 83 | 0.410 |
Why?
| | Health Promotion | 6 | 2013 | 759 | 0.410 |
Why?
| | Data Collection | 9 | 2019 | 662 | 0.410 |
Why?
| | Behavior | 1 | 2014 | 93 | 0.410 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2016 | 130 | 0.410 |
Why?
| | Lung | 12 | 2016 | 4137 | 0.410 |
Why?
| | Bronchi | 7 | 2000 | 267 | 0.400 |
Why?
| | Aerosols | 5 | 2021 | 181 | 0.400 |
Why?
| | Vanadium | 7 | 2009 | 10 | 0.400 |
Why?
| | Europe | 8 | 2024 | 411 | 0.390 |
Why?
| | Adolescent Behavior | 4 | 2016 | 538 | 0.390 |
Why?
| | Abortion, Spontaneous | 1 | 2014 | 116 | 0.390 |
Why?
| | Personnel Selection | 1 | 2014 | 87 | 0.390 |
Why?
| | Hot Temperature | 3 | 2014 | 406 | 0.390 |
Why?
| | Workplace | 5 | 2011 | 269 | 0.380 |
Why?
| | Child | 35 | 2025 | 22414 | 0.380 |
Why?
| | Medicare | 7 | 2012 | 808 | 0.380 |
Why?
| | Preventive Medicine | 1 | 2012 | 40 | 0.380 |
Why?
| | Australia | 6 | 2024 | 311 | 0.380 |
Why?
| | Regression Analysis | 10 | 2018 | 1023 | 0.370 |
Why?
| | Canada | 4 | 2024 | 429 | 0.370 |
Why?
| | Life Expectancy | 1 | 2013 | 71 | 0.370 |
Why?
| | Exercise | 4 | 2021 | 2112 | 0.370 |
Why?
| | Sex Distribution | 7 | 2019 | 381 | 0.370 |
Why?
| | Lead | 6 | 2015 | 71 | 0.370 |
Why?
| | Child Welfare | 3 | 2004 | 229 | 0.370 |
Why?
| | Surveys and Questionnaires | 27 | 2024 | 5974 | 0.370 |
Why?
| | Adolescent | 40 | 2025 | 22130 | 0.370 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2019 | 652 | 0.370 |
Why?
| | Health Surveys | 9 | 2017 | 513 | 0.360 |
Why?
| | Diabetes Mellitus | 2 | 2019 | 1077 | 0.360 |
Why?
| | Research Report | 1 | 2012 | 86 | 0.360 |
Why?
| | Genetic Predisposition to Disease | 5 | 2014 | 2375 | 0.360 |
Why?
| | Adenocarcinoma | 4 | 2017 | 896 | 0.360 |
Why?
| | Respiratory Sounds | 4 | 2024 | 109 | 0.360 |
Why?
| | Meningioma | 2 | 2010 | 95 | 0.360 |
Why?
| | Korea | 5 | 2015 | 17 | 0.360 |
Why?
| | Data Interpretation, Statistical | 5 | 2008 | 377 | 0.350 |
Why?
| | Miners | 2 | 2022 | 3 | 0.350 |
Why?
| | Coal | 3 | 2022 | 19 | 0.350 |
Why?
| | Drug and Narcotic Control | 1 | 2011 | 29 | 0.340 |
Why?
| | Leukocyte Count | 2 | 2005 | 328 | 0.340 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2015 | 658 | 0.340 |
Why?
| | Heat Stress Disorders | 2 | 2002 | 82 | 0.340 |
Why?
| | China | 8 | 2012 | 220 | 0.340 |
Why?
| | Copying Processes | 1 | 2010 | 1 | 0.340 |
Why?
| | Americas | 3 | 2019 | 28 | 0.330 |
Why?
| | Veterans Disability Claims | 1 | 2010 | 3 | 0.330 |
Why?
| | Mass Screening | 1 | 2019 | 1313 | 0.330 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2016 | 2064 | 0.330 |
Why?
| | Seasons | 10 | 2021 | 546 | 0.330 |
Why?
| | Wildfires | 2 | 2021 | 41 | 0.330 |
Why?
| | Societies, Medical | 9 | 2026 | 859 | 0.320 |
Why?
| | Education, Public Health Professional | 2 | 2008 | 8 | 0.320 |
Why?
| | Brazil | 4 | 2019 | 173 | 0.320 |
Why?
| | Congresses as Topic | 5 | 2018 | 230 | 0.320 |
Why?
| | Career Choice | 2 | 2010 | 233 | 0.320 |
Why?
| | September 11 Terrorist Attacks | 2 | 2007 | 30 | 0.320 |
Why?
| | Air Microbiology | 3 | 2024 | 48 | 0.320 |
Why?
| | Young Adult | 21 | 2025 | 13749 | 0.320 |
Why?
| | Child, Preschool | 19 | 2024 | 11512 | 0.310 |
Why?
| | Rural Health | 2 | 2007 | 83 | 0.310 |
Why?
| | Product Packaging | 3 | 2020 | 6 | 0.310 |
Why?
| | Health | 4 | 2018 | 84 | 0.310 |
Why?
| | Carcinogenesis | 2 | 2022 | 215 | 0.310 |
Why?
| | Cystic Fibrosis | 3 | 2014 | 1130 | 0.300 |
Why?
| | Hair | 6 | 2014 | 89 | 0.300 |
Why?
| | Tobacco, Smokeless | 4 | 2016 | 13 | 0.300 |
Why?
| | Blood Glucose | 4 | 2022 | 2278 | 0.300 |
Why?
| | Sex Factors | 13 | 2015 | 2063 | 0.300 |
Why?
| | Deception | 1 | 2008 | 20 | 0.290 |
Why?
| | Housing | 7 | 2011 | 146 | 0.290 |
Why?
| | Expert Testimony | 2 | 2006 | 44 | 0.290 |
Why?
| | Radiology Information Systems | 2 | 2025 | 33 | 0.290 |
Why?
| | Women's Health | 1 | 2010 | 311 | 0.280 |
Why?
| | Alcohol Drinking | 3 | 2005 | 835 | 0.280 |
Why?
| | Glioma | 2 | 2010 | 427 | 0.280 |
Why?
| | Commerce | 4 | 2021 | 80 | 0.280 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2007 | 9 | 0.270 |
Why?
| | Biomarkers | 10 | 2017 | 4190 | 0.270 |
Why?
| | Air Pollutants, Occupational | 4 | 2008 | 41 | 0.270 |
Why?
| | Information Dissemination | 2 | 2010 | 224 | 0.270 |
Why?
| | Spirometry | 4 | 2016 | 260 | 0.270 |
Why?
| | Registries | 8 | 2022 | 2144 | 0.270 |
Why?
| | Musculoskeletal Diseases | 2 | 2025 | 84 | 0.270 |
Why?
| | Construction Materials | 1 | 2007 | 17 | 0.260 |
Why?
| | Environment, Controlled | 2 | 2006 | 23 | 0.260 |
Why?
| | Evidence-Based Medicine | 6 | 2014 | 750 | 0.260 |
Why?
| | Professional Role | 3 | 2019 | 168 | 0.260 |
Why?
| | Foundations | 3 | 2018 | 29 | 0.250 |
Why?
| | Education | 2 | 2018 | 109 | 0.250 |
Why?
| | Ontario | 3 | 2019 | 95 | 0.250 |
Why?
| | Marketing | 4 | 2021 | 34 | 0.250 |
Why?
| | Growth Disorders | 1 | 2007 | 87 | 0.250 |
Why?
| | Bias | 6 | 2018 | 229 | 0.250 |
Why?
| | Social Environment | 2 | 2019 | 295 | 0.240 |
Why?
| | Academies and Institutes | 4 | 2022 | 55 | 0.240 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2765 | 0.240 |
Why?
| | Sarcoma, Small Cell | 1 | 2025 | 2 | 0.240 |
Why?
| | Los Angeles | 4 | 2024 | 75 | 0.240 |
Why?
| | Radon Daughters | 5 | 2022 | 5 | 0.240 |
Why?
| | RNA-Binding Protein FUS | 1 | 2025 | 14 | 0.240 |
Why?
| | RNA-Binding Protein EWS | 1 | 2025 | 26 | 0.240 |
Why?
| | Thoracic Neoplasms | 1 | 2026 | 39 | 0.240 |
Why?
| | National Institutes of Health (U.S.) | 3 | 2018 | 134 | 0.240 |
Why?
| | Neurofibroma, Plexiform | 1 | 2025 | 12 | 0.240 |
Why?
| | Metals | 4 | 1999 | 140 | 0.240 |
Why?
| | Publishing | 2 | 2014 | 145 | 0.230 |
Why?
| | Teaching | 1 | 2008 | 237 | 0.230 |
Why?
| | Retrospective Studies | 13 | 2025 | 16374 | 0.230 |
Why?
| | Respiratory System | 2 | 2021 | 157 | 0.230 |
Why?
| | NFATC Transcription Factors | 1 | 2025 | 94 | 0.230 |
Why?
| | Anemia | 1 | 2007 | 177 | 0.230 |
Why?
| | Bayes Theorem | 5 | 2006 | 418 | 0.230 |
Why?
| | Soft Tissue Infections | 1 | 2025 | 41 | 0.230 |
Why?
| | Disease Susceptibility | 3 | 2018 | 353 | 0.230 |
Why?
| | Sacroiliac Joint | 1 | 2025 | 34 | 0.230 |
Why?
| | Neurofibromatosis 1 | 1 | 2025 | 56 | 0.230 |
Why?
| | Myocardial Infarction | 1 | 2012 | 1069 | 0.230 |
Why?
| | Program Evaluation | 3 | 2020 | 930 | 0.230 |
Why?
| | Infant | 16 | 2016 | 9843 | 0.220 |
Why?
| | Epidemiologic Research Design | 3 | 2004 | 29 | 0.220 |
Why?
| | Radiography, Thoracic | 1 | 2006 | 179 | 0.220 |
Why?
| | Laryngeal Neoplasms | 2 | 2004 | 34 | 0.220 |
Why?
| | Age Distribution | 5 | 2013 | 397 | 0.220 |
Why?
| | Airports | 1 | 2024 | 3 | 0.220 |
Why?
| | Radiation, Ionizing | 1 | 2024 | 80 | 0.210 |
Why?
| | Lactoferrin | 3 | 1999 | 40 | 0.210 |
Why?
| | Mutagens | 1 | 2004 | 26 | 0.210 |
Why?
| | Infant, Newborn | 15 | 2016 | 6289 | 0.210 |
Why?
| | Hepatitis B | 1 | 2004 | 69 | 0.210 |
Why?
| | Cleft Palate | 2 | 2015 | 75 | 0.210 |
Why?
| | Health Personnel | 3 | 2022 | 738 | 0.210 |
Why?
| | Health Services Research | 2 | 2014 | 406 | 0.210 |
Why?
| | Epidemiological Monitoring | 7 | 2008 | 65 | 0.210 |
Why?
| | Rhinovirus | 1 | 2004 | 58 | 0.210 |
Why?
| | Mortality, Premature | 2 | 2024 | 13 | 0.210 |
Why?
| | National Health Programs | 2 | 2019 | 21 | 0.210 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2025 | 204 | 0.210 |
Why?
| | Cross-Sectional Studies | 18 | 2024 | 5697 | 0.210 |
Why?
| | Glycerol | 1 | 2024 | 91 | 0.210 |
Why?
| | Vulnerable Populations | 2 | 2015 | 170 | 0.200 |
Why?
| | Time | 2 | 2003 | 87 | 0.200 |
Why?
| | Environment Design | 1 | 2003 | 26 | 0.200 |
Why?
| | Liability, Legal | 2 | 2006 | 47 | 0.200 |
Why?
| | Medical Marijuana | 1 | 2025 | 125 | 0.200 |
Why?
| | Osteomyelitis | 1 | 2025 | 143 | 0.200 |
Why?
| | Pregnancy | 11 | 2016 | 7092 | 0.200 |
Why?
| | Hypertension | 5 | 2012 | 1254 | 0.200 |
Why?
| | Logistic Models | 10 | 2016 | 2092 | 0.200 |
Why?
| | Germ-Line Mutation | 1 | 2004 | 168 | 0.200 |
Why?
| | Brain Neoplasms | 2 | 2010 | 1305 | 0.200 |
Why?
| | Dust | 4 | 2007 | 99 | 0.200 |
Why?
| | Diabetes Complications | 1 | 2005 | 224 | 0.200 |
Why?
| | Fasting | 1 | 2005 | 284 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2025 | 253 | 0.200 |
Why?
| | Sensitivity and Specificity | 4 | 2016 | 1977 | 0.200 |
Why?
| | Travel | 1 | 2004 | 136 | 0.190 |
Why?
| | Weather | 5 | 2009 | 40 | 0.190 |
Why?
| | Disinfection | 1 | 2024 | 128 | 0.190 |
Why?
| | Databases as Topic | 4 | 2008 | 69 | 0.190 |
Why?
| | Reproducibility of Results | 6 | 2025 | 3356 | 0.190 |
Why?
| | Polonium | 3 | 1991 | 3 | 0.190 |
Why?
| | Electromagnetic Fields | 2 | 2014 | 38 | 0.190 |
Why?
| | Financial Support | 2 | 2016 | 22 | 0.180 |
Why?
| | California | 5 | 2025 | 466 | 0.180 |
Why?
| | Healthcare Disparities | 2 | 2020 | 673 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 1 | 2005 | 501 | 0.180 |
Why?
| | Engineering | 1 | 2022 | 29 | 0.180 |
Why?
| | Pfiesteria piscicida | 1 | 2001 | 1 | 0.180 |
Why?
| | Shoulder Joint | 1 | 2024 | 177 | 0.180 |
Why?
| | Nickel | 4 | 2009 | 62 | 0.180 |
Why?
| | Protozoan Infections | 1 | 2001 | 11 | 0.180 |
Why?
| | Risk Management | 3 | 2008 | 93 | 0.180 |
Why?
| | Recurrence | 2 | 2019 | 1111 | 0.180 |
Why?
| | Analgesics | 1 | 2023 | 226 | 0.180 |
Why?
| | Lumbosacral Plexus | 1 | 2021 | 9 | 0.180 |
Why?
| | Estrogen Replacement Therapy | 1 | 2002 | 142 | 0.180 |
Why?
| | Baltimore | 5 | 2014 | 68 | 0.180 |
Why?
| | Gases | 2 | 2007 | 50 | 0.180 |
Why?
| | Diagnosis, Differential | 3 | 2026 | 1502 | 0.180 |
Why?
| | Pulmonary Fibrosis | 3 | 2000 | 399 | 0.180 |
Why?
| | Policy Making | 4 | 2012 | 100 | 0.170 |
Why?
| | Plants, Toxic | 2 | 1998 | 26 | 0.170 |
Why?
| | Maximum Allowable Concentration | 2 | 2015 | 16 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2004 | 353 | 0.170 |
Why?
| | Hyperglycemia | 1 | 2005 | 365 | 0.170 |
Why?
| | Residence Characteristics | 4 | 2018 | 368 | 0.170 |
Why?
| | Bismuth | 2 | 1991 | 3 | 0.170 |
Why?
| | SEER Program | 2 | 2021 | 221 | 0.170 |
Why?
| | Reproduction | 2 | 2001 | 206 | 0.170 |
Why?
| | Receptors, Cell Surface | 2 | 2001 | 398 | 0.170 |
Why?
| | Extremities | 3 | 2024 | 140 | 0.170 |
Why?
| | Patient Admission | 3 | 2012 | 203 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2024 | 274 | 0.160 |
Why?
| | Medicine | 1 | 2022 | 125 | 0.160 |
Why?
| | Confidentiality | 2 | 2019 | 74 | 0.160 |
Why?
| | Poisson Distribution | 3 | 2012 | 77 | 0.160 |
Why?
| | Competency-Based Education | 1 | 2020 | 75 | 0.160 |
Why?
| | Health Priorities | 4 | 2010 | 44 | 0.160 |
Why?
| | Conflict of Interest | 1 | 2001 | 130 | 0.160 |
Why?
| | Clinical Medicine | 1 | 2000 | 25 | 0.160 |
Why?
| | Follow-Up Studies | 10 | 2020 | 5212 | 0.160 |
Why?
| | Arachidonic Acid | 3 | 2001 | 126 | 0.160 |
Why?
| | Panama | 1 | 2019 | 14 | 0.160 |
Why?
| | Minnesota | 3 | 2009 | 169 | 0.160 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 482 | 0.150 |
Why?
| | Talc | 1 | 2019 | 8 | 0.150 |
Why?
| | Carbon | 5 | 2009 | 204 | 0.150 |
Why?
| | Petroleum Pollution | 1 | 2019 | 10 | 0.150 |
Why?
| | Public Health Surveillance | 1 | 2020 | 84 | 0.150 |
Why?
| | Biodiversity | 1 | 2023 | 425 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2023 | 337 | 0.150 |
Why?
| | Animals | 18 | 2020 | 37749 | 0.150 |
Why?
| | Mast Cells | 2 | 2001 | 153 | 0.150 |
Why?
| | Models, Theoretical | 5 | 2014 | 584 | 0.150 |
Why?
| | Policy | 2 | 2021 | 149 | 0.150 |
Why?
| | Licensure | 1 | 2019 | 13 | 0.150 |
Why?
| | Peripheral Nerve Injuries | 1 | 2019 | 38 | 0.150 |
Why?
| | Authorship | 1 | 1999 | 54 | 0.150 |
Why?
| | Arsenic | 1 | 1999 | 63 | 0.150 |
Why?
| | Catholicism | 1 | 2018 | 9 | 0.150 |
Why?
| | Mental Health | 1 | 2025 | 759 | 0.150 |
Why?
| | Molecular Epidemiology | 2 | 2009 | 72 | 0.150 |
Why?
| | Disasters | 3 | 2018 | 100 | 0.140 |
Why?
| | HIV Infections | 5 | 2016 | 3022 | 0.140 |
Why?
| | Weight Gain | 1 | 2002 | 539 | 0.140 |
Why?
| | Prognosis | 8 | 2026 | 4080 | 0.140 |
Why?
| | Emergency Service, Hospital | 2 | 2009 | 2193 | 0.140 |
Why?
| | Social Responsibility | 1 | 2018 | 52 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2004 | 741 | 0.140 |
Why?
| | Human Migration | 1 | 2018 | 24 | 0.140 |
Why?
| | Greenhouse Gases | 1 | 2018 | 8 | 0.140 |
Why?
| | Transferrin | 1 | 1998 | 50 | 0.140 |
Why?
| | Glycine | 1 | 2019 | 185 | 0.140 |
Why?
| | Veterans | 1 | 2010 | 1525 | 0.140 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 1999 | 168 | 0.140 |
Why?
| | Models, Biological | 4 | 2015 | 1828 | 0.140 |
Why?
| | Radiobiology | 1 | 2017 | 6 | 0.140 |
Why?
| | Writing | 1 | 1999 | 101 | 0.140 |
Why?
| | Frail Elderly | 1 | 1999 | 133 | 0.140 |
Why?
| | Poverty | 3 | 2023 | 530 | 0.140 |
Why?
| | Restaurants | 3 | 2012 | 23 | 0.140 |
Why?
| | Health Communication | 1 | 2018 | 48 | 0.140 |
Why?
| | Cross-Over Studies | 4 | 2022 | 582 | 0.140 |
Why?
| | Sleep | 3 | 2018 | 885 | 0.140 |
Why?
| | Ferritins | 4 | 1998 | 67 | 0.140 |
Why?
| | Antioxidants | 1 | 2001 | 599 | 0.130 |
Why?
| | Cross-Cultural Comparison | 3 | 1994 | 85 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 276 | 0.130 |
Why?
| | Heating | 3 | 2007 | 18 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2021 | 569 | 0.130 |
Why?
| | Air | 2 | 2010 | 43 | 0.130 |
Why?
| | Bronchitis, Chronic | 1 | 2017 | 24 | 0.130 |
Why?
| | Pulmonary Medicine | 2 | 2017 | 83 | 0.130 |
Why?
| | Economics | 1 | 2017 | 11 | 0.130 |
Why?
| | Public Health Administration | 1 | 2018 | 74 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2537 | 0.130 |
Why?
| | Industry | 2 | 2010 | 68 | 0.130 |
Why?
| | Social Class | 3 | 2017 | 268 | 0.130 |
Why?
| | Occupational Health | 1 | 1999 | 208 | 0.130 |
Why?
| | Environment | 2 | 2012 | 342 | 0.130 |
Why?
| | Universities | 2 | 2016 | 454 | 0.130 |
Why?
| | Radiation Dosage | 4 | 2007 | 191 | 0.130 |
Why?
| | Periodicals as Topic | 1 | 1999 | 217 | 0.130 |
Why?
| | Algorithms | 5 | 2026 | 1768 | 0.130 |
Why?
| | Dioxins | 1 | 1996 | 7 | 0.130 |
Why?
| | Stem Cell Factor | 1 | 1996 | 17 | 0.120 |
Why?
| | Publication Bias | 2 | 2008 | 42 | 0.120 |
Why?
| | Ferric Compounds | 1 | 1997 | 55 | 0.120 |
Why?
| | Iran | 1 | 2016 | 44 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1130 | 0.120 |
Why?
| | Zinc | 1 | 1999 | 299 | 0.120 |
Why?
| | Peer Influence | 1 | 2016 | 13 | 0.120 |
Why?
| | North America | 4 | 2021 | 307 | 0.120 |
Why?
| | Product Labeling | 1 | 2016 | 10 | 0.120 |
Why?
| | Eating | 1 | 2018 | 392 | 0.120 |
Why?
| | Capacity Building | 1 | 2016 | 62 | 0.120 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 2 | 2007 | 27 | 0.120 |
Why?
| | Xenobiotics | 1 | 1995 | 32 | 0.120 |
Why?
| | Emigrants and Immigrants | 1 | 2018 | 149 | 0.120 |
Why?
| | Coinfection | 1 | 2016 | 137 | 0.120 |
Why?
| | Socioeconomic Factors | 5 | 2016 | 1317 | 0.120 |
Why?
| | Polychlorinated Dibenzodioxins | 2 | 2010 | 8 | 0.110 |
Why?
| | Air Pollution, Radioactive | 1 | 1994 | 2 | 0.110 |
Why?
| | Asia | 4 | 2024 | 70 | 0.110 |
Why?
| | Schools, Medical | 1 | 2016 | 152 | 0.110 |
Why?
| | Internationality | 1 | 2016 | 158 | 0.110 |
Why?
| | Cooking | 2 | 2023 | 66 | 0.110 |
Why?
| | Insurance, Health | 2 | 2009 | 299 | 0.110 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2014 | 317 | 0.110 |
Why?
| | Motivation | 1 | 2020 | 603 | 0.110 |
Why?
| | Radiation Effects | 2 | 2004 | 7 | 0.110 |
Why?
| | Primary Health Care | 1 | 2005 | 1809 | 0.110 |
Why?
| | Oxidants | 1 | 1994 | 112 | 0.110 |
Why?
| | PubMed | 1 | 2014 | 11 | 0.110 |
Why?
| | Latin America | 1 | 2014 | 91 | 0.110 |
Why?
| | Cleft Lip | 1 | 2014 | 59 | 0.100 |
Why?
| | Pelvic Bones | 1 | 2016 | 129 | 0.100 |
Why?
| | Silicosis | 1 | 1994 | 29 | 0.100 |
Why?
| | Temperature | 5 | 2005 | 669 | 0.100 |
Why?
| | Mastectomy, Segmental | 1 | 1994 | 101 | 0.100 |
Why?
| | Ganglionic Stimulants | 2 | 2015 | 15 | 0.100 |
Why?
| | Mucus | 1 | 1994 | 78 | 0.100 |
Why?
| | Review Literature as Topic | 1 | 2014 | 72 | 0.100 |
Why?
| | Drug Synergism | 1 | 2014 | 375 | 0.100 |
Why?
| | Breast | 1 | 1994 | 158 | 0.100 |
Why?
| | Health Plan Implementation | 1 | 2014 | 145 | 0.100 |
Why?
| | Community Networks | 1 | 2013 | 58 | 0.100 |
Why?
| | Analysis of Variance | 4 | 2009 | 1321 | 0.100 |
Why?
| | Benzene | 2 | 2023 | 18 | 0.100 |
Why?
| | Taxes | 2 | 2010 | 15 | 0.100 |
Why?
| | History, 19th Century | 1 | 2013 | 61 | 0.100 |
Why?
| | Bone and Bones | 1 | 2016 | 317 | 0.100 |
Why?
| | Iron | 4 | 1999 | 324 | 0.100 |
Why?
| | Greenhouse Effect | 3 | 2001 | 10 | 0.100 |
Why?
| | American Cancer Society | 2 | 2009 | 5 | 0.100 |
Why?
| | Administration, Inhalation | 2 | 2005 | 594 | 0.100 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2012 | 17 | 0.100 |
Why?
| | Names | 1 | 2012 | 14 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2024 | 194 | 0.100 |
Why?
| | Snoring | 2 | 2010 | 18 | 0.100 |
Why?
| | Local Government | 1 | 2012 | 27 | 0.090 |
Why?
| | Calpain | 1 | 2012 | 60 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1127 | 0.090 |
Why?
| | Program Development | 1 | 2014 | 368 | 0.090 |
Why?
| | Inflammation | 4 | 2023 | 2902 | 0.090 |
Why?
| | Sodium, Dietary | 1 | 2012 | 39 | 0.090 |
Why?
| | Allergens | 2 | 2014 | 401 | 0.090 |
Why?
| | United Kingdom | 2 | 2006 | 322 | 0.090 |
Why?
| | Nonlinear Dynamics | 2 | 2003 | 92 | 0.090 |
Why?
| | Feeding Behavior | 1 | 1998 | 682 | 0.090 |
Why?
| | TRPM Cation Channels | 1 | 2012 | 75 | 0.090 |
Why?
| | Sampling Studies | 2 | 2006 | 102 | 0.090 |
Why?
| | Diet, Carbohydrate-Restricted | 2 | 2022 | 37 | 0.090 |
Why?
| | Maryland | 2 | 2008 | 63 | 0.090 |
Why?
| | Public Facilities | 2 | 2008 | 5 | 0.090 |
Why?
| | Eosinophils | 1 | 2014 | 326 | 0.090 |
Why?
| | Pennsylvania | 5 | 2006 | 134 | 0.090 |
Why?
| | Body Temperature | 2 | 2002 | 224 | 0.090 |
Why?
| | Ethiopia | 2 | 2021 | 41 | 0.090 |
Why?
| | Students, Medical | 1 | 2016 | 369 | 0.090 |
Why?
| | Sick Building Syndrome | 1 | 2011 | 4 | 0.090 |
Why?
| | Communicable Diseases | 2 | 2011 | 161 | 0.090 |
Why?
| | Crime | 1 | 2011 | 60 | 0.080 |
Why?
| | Printing | 1 | 2010 | 5 | 0.080 |
Why?
| | Manufactured Materials | 1 | 2010 | 8 | 0.080 |
Why?
| | Cell Line, Transformed | 3 | 1999 | 145 | 0.080 |
Why?
| | Self Report | 4 | 2017 | 861 | 0.080 |
Why?
| | Pregnancy, Ectopic | 1 | 1991 | 54 | 0.080 |
Why?
| | Defoliants, Chemical | 1 | 2010 | 1 | 0.080 |
Why?
| | Agent Orange | 1 | 2010 | 2 | 0.080 |
Why?
| | 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2010 | 2 | 0.080 |
Why?
| | Aging | 2 | 2002 | 1924 | 0.080 |
Why?
| | Maternal Welfare | 1 | 2010 | 20 | 0.080 |
Why?
| | 2,4-Dichlorophenoxyacetic Acid | 1 | 2010 | 13 | 0.080 |
Why?
| | Waist Circumference | 1 | 2010 | 134 | 0.080 |
Why?
| | Lung Diseases, Obstructive | 2 | 1988 | 44 | 0.080 |
Why?
| | Prostatic Neoplasms | 3 | 1996 | 1049 | 0.080 |
Why?
| | New York City | 2 | 2007 | 87 | 0.080 |
Why?
| | Curriculum | 2 | 2008 | 1039 | 0.080 |
Why?
| | Suicide | 1 | 2017 | 671 | 0.080 |
Why?
| | Water Pollution | 2 | 2018 | 9 | 0.080 |
Why?
| | Developed Countries | 1 | 2010 | 39 | 0.080 |
Why?
| | Legislation as Topic | 1 | 2009 | 5 | 0.080 |
Why?
| | Disclosure | 1 | 2010 | 112 | 0.080 |
Why?
| | Legislation, Medical | 1 | 2009 | 11 | 0.080 |
Why?
| | Carcinoma | 2 | 2007 | 230 | 0.080 |
Why?
| | Radioactive Pollutants | 1 | 1989 | 1 | 0.080 |
Why?
| | Medical Record Linkage | 2 | 2013 | 68 | 0.080 |
Why?
| | Monte Carlo Method | 1 | 2009 | 150 | 0.080 |
Why?
| | Food Contamination, Radioactive | 1 | 1989 | 1 | 0.080 |
Why?
| | Radioisotopes | 1 | 1989 | 36 | 0.080 |
Why?
| | Survival Rate | 5 | 2009 | 1972 | 0.080 |
Why?
| | Birth Weight | 1 | 2012 | 515 | 0.080 |
Why?
| | Models, Econometric | 1 | 2009 | 36 | 0.080 |
Why?
| | Cooperative Behavior | 2 | 2018 | 463 | 0.070 |
Why?
| | Costs and Cost Analysis | 1 | 2010 | 222 | 0.070 |
Why?
| | Phospholipases A | 2 | 2001 | 104 | 0.070 |
Why?
| | Gallbladder Diseases | 1 | 1988 | 12 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 136 | 0.070 |
Why?
| | New York | 2 | 2010 | 128 | 0.070 |
Why?
| | ROC Curve | 1 | 2010 | 590 | 0.070 |
Why?
| | Nicotinic Antagonists | 1 | 2008 | 36 | 0.070 |
Why?
| | Health Education | 3 | 2014 | 364 | 0.070 |
Why?
| | Interdisciplinary Communication | 2 | 2011 | 193 | 0.070 |
Why?
| | Epithelial Cells | 6 | 2000 | 1114 | 0.070 |
Why?
| | Decision Making | 3 | 2010 | 961 | 0.070 |
Why?
| | Students, Public Health | 1 | 2008 | 1 | 0.070 |
Why?
| | DNA Damage | 2 | 2004 | 429 | 0.070 |
Why?
| | Computer Simulation | 2 | 2009 | 1015 | 0.070 |
Why?
| | Nutrition Surveys | 2 | 2012 | 280 | 0.070 |
Why?
| | Dyspnea | 3 | 2024 | 257 | 0.070 |
Why?
| | Cells, Cultured | 6 | 2012 | 4212 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 1991 | 457 | 0.070 |
Why?
| | Signal Transduction | 3 | 2003 | 5169 | 0.070 |
Why?
| | Epidemiologic Factors | 2 | 2002 | 10 | 0.070 |
Why?
| | Bone Marrow Cells | 2 | 2001 | 327 | 0.070 |
Why?
| | Bronchial Hyperreactivity | 1 | 2008 | 104 | 0.070 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 1 | 2007 | 87 | 0.070 |
Why?
| | Financing, Government | 2 | 2004 | 50 | 0.070 |
Why?
| | Coal Ash | 4 | 2000 | 8 | 0.070 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.070 |
Why?
| | Rescue Work | 1 | 2007 | 11 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2010 | 2075 | 0.070 |
Why?
| | Menopause | 2 | 2002 | 320 | 0.070 |
Why?
| | Polysomnography | 5 | 2009 | 241 | 0.070 |
Why?
| | Overweight | 2 | 2016 | 588 | 0.070 |
Why?
| | Automobile Driving | 1 | 2009 | 152 | 0.070 |
Why?
| | Insurance Coverage | 1 | 2009 | 239 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2014 | 962 | 0.070 |
Why?
| | Genome-Wide Association Study | 2 | 2014 | 1406 | 0.060 |
Why?
| | Tars | 1 | 2006 | 5 | 0.060 |
Why?
| | Schools, Public Health | 1 | 2006 | 4 | 0.060 |
Why?
| | Poland | 1 | 2006 | 35 | 0.060 |
Why?
| | Chromatography, Gas | 1 | 2006 | 33 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 619 | 0.060 |
Why?
| | Forced Expiratory Volume | 3 | 2016 | 484 | 0.060 |
Why?
| | Multivariate Analysis | 5 | 2009 | 1498 | 0.060 |
Why?
| | Energy Intake | 2 | 2001 | 513 | 0.060 |
Why?
| | Geography | 2 | 2008 | 201 | 0.060 |
Why?
| | Quality Improvement | 1 | 2015 | 1254 | 0.060 |
Why?
| | Biomass | 1 | 2007 | 113 | 0.060 |
Why?
| | Survival Analysis | 2 | 2004 | 1320 | 0.060 |
Why?
| | NF-kappa B | 3 | 2001 | 692 | 0.060 |
Why?
| | Sulfur Dioxide | 4 | 2001 | 13 | 0.060 |
Why?
| | Single Person | 1 | 1986 | 7 | 0.060 |
Why?
| | Cattle | 1 | 1989 | 998 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2009 | 434 | 0.060 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 1570 | 0.060 |
Why?
| | Students | 3 | 2016 | 648 | 0.060 |
Why?
| | Fires | 1 | 2007 | 89 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2009 | 610 | 0.060 |
Why?
| | Gift Giving | 1 | 2006 | 11 | 0.060 |
Why?
| | Sleep Stages | 1 | 2006 | 76 | 0.060 |
Why?
| | Cough | 1 | 2007 | 133 | 0.060 |
Why?
| | Computer-Assisted Instruction | 1 | 2006 | 68 | 0.060 |
Why?
| | Health Status | 2 | 2020 | 824 | 0.060 |
Why?
| | Models, Educational | 1 | 2006 | 95 | 0.060 |
Why?
| | Thinness | 1 | 2006 | 96 | 0.060 |
Why?
| | Biological Specimen Banks | 1 | 2006 | 99 | 0.060 |
Why?
| | Interinstitutional Relations | 1 | 2006 | 54 | 0.060 |
Why?
| | Bioterrorism | 1 | 2006 | 31 | 0.060 |
Why?
| | Consensus | 1 | 2008 | 547 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2012 | 951 | 0.060 |
Why?
| | Peripheral Arterial Disease | 1 | 2012 | 490 | 0.060 |
Why?
| | Meta-Analysis as Topic | 1 | 2006 | 185 | 0.060 |
Why?
| | Education, Distance | 1 | 2006 | 56 | 0.060 |
Why?
| | Behavior, Addictive | 1 | 2006 | 89 | 0.060 |
Why?
| | United States Department of Veterans Affairs | 1 | 2010 | 711 | 0.060 |
Why?
| | Rats | 4 | 1998 | 5637 | 0.060 |
Why?
| | Interviews as Topic | 4 | 2010 | 854 | 0.060 |
Why?
| | Communicable Disease Control | 1 | 2006 | 83 | 0.060 |
Why?
| | Goals | 1 | 2007 | 179 | 0.060 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2004 | 23 | 0.060 |
Why?
| | Deferoxamine | 3 | 1999 | 26 | 0.060 |
Why?
| | Stroke | 1 | 2013 | 1158 | 0.060 |
Why?
| | Mexican Americans | 2 | 2018 | 114 | 0.060 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2938 | 0.060 |
Why?
| | Financing, Organized | 1 | 2004 | 39 | 0.050 |
Why?
| | Uruguay | 1 | 2004 | 2 | 0.050 |
Why?
| | Paraguay | 1 | 2004 | 3 | 0.050 |
Why?
| | Disaster Planning | 1 | 2006 | 97 | 0.050 |
Why?
| | Costa Rica | 1 | 2004 | 18 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2008 | 752 | 0.050 |
Why?
| | Argentina | 1 | 2004 | 28 | 0.050 |
Why?
| | Chile | 1 | 2004 | 24 | 0.050 |
Why?
| | Spermatogonia | 1 | 2004 | 14 | 0.050 |
Why?
| | Observer Variation | 1 | 2025 | 357 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2015 | 645 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 1999 | 1739 | 0.050 |
Why?
| | Tandem Repeat Sequences | 1 | 2004 | 20 | 0.050 |
Why?
| | Diet Surveys | 1 | 1984 | 91 | 0.050 |
Why?
| | No-Observed-Adverse-Effect Level | 1 | 2004 | 6 | 0.050 |
Why?
| | Peru | 1 | 2004 | 61 | 0.050 |
Why?
| | Electroencephalography | 1 | 2007 | 524 | 0.050 |
Why?
| | Diet | 4 | 2003 | 1282 | 0.050 |
Why?
| | Uganda | 1 | 2024 | 87 | 0.050 |
Why?
| | Picornaviridae | 1 | 2004 | 20 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2005 | 196 | 0.050 |
Why?
| | Mentors | 2 | 2003 | 212 | 0.050 |
Why?
| | Aircraft | 1 | 2004 | 22 | 0.050 |
Why?
| | Shoulder Pain | 1 | 2024 | 32 | 0.050 |
Why?
| | Nose Diseases | 1 | 2004 | 18 | 0.050 |
Why?
| | Ear Diseases | 1 | 2004 | 17 | 0.050 |
Why?
| | Propylene Glycols | 1 | 2024 | 28 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2004 | 76 | 0.050 |
Why?
| | Aerospace Medicine | 1 | 2004 | 33 | 0.050 |
Why?
| | Sugars | 1 | 2024 | 41 | 0.050 |
Why?
| | Picornaviridae Infections | 1 | 2004 | 51 | 0.050 |
Why?
| | Saskatchewan | 1 | 2003 | 8 | 0.050 |
Why?
| | Decision Support Techniques | 1 | 2008 | 431 | 0.050 |
Why?
| | Shoulder | 1 | 2024 | 93 | 0.050 |
Why?
| | Nasal Mucosa | 1 | 2004 | 111 | 0.050 |
Why?
| | Fourier Analysis | 1 | 2003 | 40 | 0.050 |
Why?
| | Observation | 1 | 2003 | 56 | 0.050 |
Why?
| | Chicago | 1 | 2003 | 61 | 0.050 |
Why?
| | Probability | 2 | 2003 | 309 | 0.050 |
Why?
| | Food | 1 | 1984 | 163 | 0.050 |
Why?
| | Free Radical Scavengers | 4 | 2012 | 87 | 0.050 |
Why?
| | Computing Methodologies | 1 | 2003 | 3 | 0.050 |
Why?
| | Maps as Topic | 1 | 2003 | 5 | 0.050 |
Why?
| | Wakefulness | 1 | 2004 | 172 | 0.050 |
Why?
| | Phosphotyrosine | 2 | 2000 | 40 | 0.050 |
Why?
| | Terminology as Topic | 1 | 1985 | 244 | 0.050 |
Why?
| | Coroners and Medical Examiners | 1 | 2022 | 8 | 0.050 |
Why?
| | Maternal-Fetal Exchange | 2 | 2015 | 172 | 0.050 |
Why?
| | Efficiency | 1 | 2003 | 101 | 0.050 |
Why?
| | Washington | 1 | 2003 | 160 | 0.050 |
Why?
| | Genomics | 1 | 2008 | 815 | 0.050 |
Why?
| | Geographic Information Systems | 1 | 2003 | 46 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2021 | 1401 | 0.050 |
Why?
| | Income | 2 | 1994 | 201 | 0.050 |
Why?
| | Body Constitution | 1 | 2002 | 54 | 0.050 |
Why?
| | Steroids | 1 | 2003 | 163 | 0.050 |
Why?
| | Nitrosamines | 2 | 2012 | 9 | 0.050 |
Why?
| | Sleep Wake Disorders | 1 | 2006 | 308 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2004 | 241 | 0.050 |
Why?
| | Peer Group | 1 | 2004 | 247 | 0.050 |
Why?
| | Epidemiologic Measurements | 1 | 2001 | 1 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2006 | 521 | 0.050 |
Why?
| | Macrophages, Alveolar | 2 | 1997 | 396 | 0.050 |
Why?
| | Joint Instability | 1 | 2024 | 168 | 0.050 |
Why?
| | Toxins, Biological | 1 | 2001 | 12 | 0.050 |
Why?
| | Chelating Agents | 2 | 1999 | 74 | 0.050 |
Why?
| | Internet | 1 | 2006 | 690 | 0.040 |
Why?
| | Invertebrates | 1 | 2001 | 25 | 0.040 |
Why?
| | France | 1 | 2021 | 39 | 0.040 |
Why?
| | Philadelphia | 2 | 1998 | 53 | 0.040 |
Why?
| | Vitamin A | 3 | 1987 | 57 | 0.040 |
Why?
| | Likelihood Functions | 1 | 2001 | 147 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 1988 | 881 | 0.040 |
Why?
| | Schizophrenia | 1 | 2025 | 454 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2008 | 11181 | 0.040 |
Why?
| | Sinusitis | 1 | 2004 | 239 | 0.040 |
Why?
| | Fishes | 1 | 2001 | 110 | 0.040 |
Why?
| | Food Chain | 1 | 2001 | 46 | 0.040 |
Why?
| | Germany | 1 | 2021 | 132 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2023 | 424 | 0.040 |
Why?
| | Population Dynamics | 1 | 2001 | 153 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2016 | 1989 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2002 | 771 | 0.040 |
Why?
| | Pilot Projects | 1 | 2006 | 1826 | 0.040 |
Why?
| | Postmenopause | 1 | 2002 | 371 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2010 | 1406 | 0.040 |
Why?
| | Mathematics | 1 | 2000 | 103 | 0.040 |
Why?
| | Respiratory Hypersensitivity | 1 | 2000 | 68 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2002 | 337 | 0.040 |
Why?
| | Stem Cells | 1 | 2004 | 603 | 0.040 |
Why?
| | Chromosome Deletion | 2 | 1997 | 118 | 0.040 |
Why?
| | Drug Interactions | 2 | 2003 | 406 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 1999 | 44 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1999 | 47 | 0.040 |
Why?
| | Smoking Water Pipes | 1 | 2019 | 9 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2002 | 412 | 0.040 |
Why?
| | Health Status Indicators | 2 | 2000 | 163 | 0.040 |
Why?
| | Culture Media | 1 | 1999 | 163 | 0.040 |
Why?
| | Religious Personnel | 1 | 2018 | 1 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 1999 | 146 | 0.040 |
Why?
| | Bibliometrics | 1 | 1999 | 65 | 0.040 |
Why?
| | Fossil Fuels | 2 | 2001 | 10 | 0.040 |
Why?
| | Heart Rate | 1 | 2002 | 821 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2000 | 317 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 1998 | 650 | 0.040 |
Why?
| | Activities of Daily Living | 2 | 1993 | 427 | 0.040 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2000 | 235 | 0.040 |
Why?
| | Maternal Age | 1 | 1998 | 128 | 0.040 |
Why?
| | Acculturation | 1 | 2018 | 55 | 0.030 |
Why?
| | Copper | 1 | 1998 | 115 | 0.030 |
Why?
| | Anthropometry | 1 | 2018 | 208 | 0.030 |
Why?
| | DNA Adducts | 1 | 1997 | 16 | 0.030 |
Why?
| | Benzo(a)pyrene | 1 | 1997 | 8 | 0.030 |
Why?
| | Mice | 4 | 2008 | 18109 | 0.030 |
Why?
| | Clinical Competence | 1 | 2025 | 1205 | 0.030 |
Why?
| | Arizona | 2 | 2006 | 81 | 0.030 |
Why?
| | Lactation | 1 | 1998 | 192 | 0.030 |
Why?
| | Stakeholder Participation | 1 | 2018 | 83 | 0.030 |
Why?
| | Interleukin-6 | 2 | 1998 | 792 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 99 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 791 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2019 | 560 | 0.030 |
Why?
| | HIV Seronegativity | 1 | 1996 | 30 | 0.030 |
Why?
| | Marriage | 3 | 1987 | 123 | 0.030 |
Why?
| | Multilevel Analysis | 1 | 2016 | 35 | 0.030 |
Why?
| | Silicon Dioxide | 1 | 1997 | 118 | 0.030 |
Why?
| | Social Support | 2 | 1993 | 633 | 0.030 |
Why?
| | Mice, Inbred CBA | 1 | 1996 | 54 | 0.030 |
Why?
| | Needs Assessment | 1 | 1999 | 385 | 0.030 |
Why?
| | Chemical Industry | 1 | 1996 | 11 | 0.030 |
Why?
| | Phospholipases A2 | 1 | 1996 | 83 | 0.030 |
Why?
| | New Zealand | 1 | 2016 | 55 | 0.030 |
Why?
| | Body Weight | 1 | 2021 | 997 | 0.030 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 1996 | 42 | 0.030 |
Why?
| | Head and Neck Neoplasms | 1 | 2001 | 555 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 1998 | 363 | 0.030 |
Why?
| | Acetylcysteine | 2 | 2012 | 144 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2006 | 4421 | 0.030 |
Why?
| | Government Agencies | 1 | 1995 | 17 | 0.030 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2016 | 102 | 0.030 |
Why?
| | Eicosanoids | 1 | 1996 | 63 | 0.030 |
Why?
| | South Africa | 1 | 2016 | 240 | 0.030 |
Why?
| | Genotype | 2 | 2014 | 1866 | 0.030 |
Why?
| | Africa, Central | 1 | 2015 | 6 | 0.030 |
Why?
| | Indians, Central American | 1 | 2015 | 6 | 0.030 |
Why?
| | Asia, Southeastern | 1 | 2015 | 12 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1999 | 855 | 0.030 |
Why?
| | Central America | 1 | 2015 | 24 | 0.030 |
Why?
| | Indians, South American | 1 | 2015 | 22 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 1998 | 2525 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 1996 | 441 | 0.030 |
Why?
| | Educational Status | 2 | 1996 | 464 | 0.030 |
Why?
| | Demography | 2 | 2000 | 296 | 0.030 |
Why?
| | Neoplasms, Experimental | 1 | 1996 | 174 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1999 | 748 | 0.030 |
Why?
| | Homosexuality, Male | 1 | 1996 | 209 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 1997 | 334 | 0.030 |
Why?
| | Random Allocation | 1 | 1995 | 367 | 0.030 |
Why?
| | Carbohydrate Sequence | 1 | 1994 | 28 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1634 | 0.030 |
Why?
| | Animals, Newborn | 1 | 1997 | 870 | 0.030 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2015 | 116 | 0.030 |
Why?
| | Breast Feeding | 1 | 1998 | 444 | 0.030 |
Why?
| | Cytokines | 2 | 2003 | 2100 | 0.030 |
Why?
| | Population Density | 1 | 1994 | 97 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2014 | 255 | 0.030 |
Why?
| | Confidence Intervals | 2 | 2009 | 329 | 0.030 |
Why?
| | Patient Care Team | 1 | 1999 | 673 | 0.030 |
Why?
| | Occupations | 2 | 2000 | 50 | 0.030 |
Why?
| | Hydrocarbons | 1 | 1993 | 30 | 0.030 |
Why?
| | Mental Competency | 1 | 1993 | 25 | 0.030 |
Why?
| | Ecosystem | 1 | 2018 | 583 | 0.020 |
Why?
| | Heart Failure | 1 | 2006 | 2093 | 0.020 |
Why?
| | Fatty Acids | 1 | 1996 | 450 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1999 | 1158 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 286 | 0.020 |
Why?
| | Transportation of Patients | 1 | 1993 | 60 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1363 | 0.020 |
Why?
| | Family Health | 1 | 1994 | 194 | 0.020 |
Why?
| | Ecology | 1 | 1994 | 119 | 0.020 |
Why?
| | Vital Statistics | 1 | 1992 | 5 | 0.020 |
Why?
| | Cadmium | 1 | 2012 | 68 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 1994 | 2929 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1083 | 0.020 |
Why?
| | Electric Impedance | 1 | 2012 | 112 | 0.020 |
Why?
| | Permeability | 1 | 2012 | 166 | 0.020 |
Why?
| | Genes, p53 | 1 | 1992 | 68 | 0.020 |
Why?
| | Genes, ras | 1 | 1992 | 95 | 0.020 |
Why?
| | Physical Fitness | 1 | 1993 | 206 | 0.020 |
Why?
| | Africa | 1 | 2012 | 119 | 0.020 |
Why?
| | Drug Evaluation | 1 | 2011 | 84 | 0.020 |
Why?
| | Alleles | 1 | 2014 | 891 | 0.020 |
Why?
| | Otitis Media | 1 | 1994 | 171 | 0.020 |
Why?
| | Quality of Life | 1 | 2003 | 3014 | 0.020 |
Why?
| | Sick Leave | 1 | 2011 | 15 | 0.020 |
Why?
| | Safety | 1 | 1993 | 356 | 0.020 |
Why?
| | Recreation | 1 | 2011 | 26 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4629 | 0.020 |
Why?
| | Survivors | 2 | 2004 | 504 | 0.020 |
Why?
| | HIV-1 | 1 | 2016 | 895 | 0.020 |
Why?
| | Macrophages | 1 | 1998 | 1562 | 0.020 |
Why?
| | RNA, Messenger | 4 | 1998 | 2828 | 0.020 |
Why?
| | Dichlorodiphenyldichloroethane | 1 | 2009 | 1 | 0.020 |
Why?
| | Disease Progression | 1 | 1998 | 2800 | 0.020 |
Why?
| | Coffee | 1 | 2009 | 14 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2009 | 61 | 0.020 |
Why?
| | Mass Media | 1 | 2010 | 45 | 0.020 |
Why?
| | Health Services | 1 | 1990 | 118 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2014 | 444 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2012 | 634 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2009 | 125 | 0.020 |
Why?
| | Thorium | 1 | 1989 | 2 | 0.020 |
Why?
| | Ether | 1 | 2009 | 8 | 0.020 |
Why?
| | Radium | 1 | 1989 | 4 | 0.020 |
Why?
| | Metallurgy | 1 | 1989 | 9 | 0.020 |
Why?
| | Methylene Chloride | 1 | 2009 | 5 | 0.020 |
Why?
| | Colorectal Neoplasms | 2 | 1996 | 805 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1990 | 152 | 0.020 |
Why?
| | Culture | 1 | 2010 | 130 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 1993 | 1093 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 1998 | 2608 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 1992 | 528 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 557 | 0.020 |
Why?
| | Taiwan | 1 | 2008 | 46 | 0.020 |
Why?
| | Death Certificates | 1 | 1988 | 30 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1996 | 2006 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2010 | 241 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2903 | 0.020 |
Why?
| | Liver | 1 | 1997 | 1820 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 1990 | 246 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1994 | 587 | 0.020 |
Why?
| | Industrial Waste | 1 | 2008 | 6 | 0.020 |
Why?
| | Ovalbumin | 1 | 2008 | 197 | 0.020 |
Why?
| | Welding | 1 | 1987 | 2 | 0.020 |
Why?
| | Government Programs | 1 | 2008 | 26 | 0.020 |
Why?
| | Texas | 1 | 1988 | 262 | 0.020 |
Why?
| | Paint | 1 | 1987 | 9 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2009 | 227 | 0.020 |
Why?
| | Forced Expiratory Flow Rates | 1 | 1987 | 10 | 0.020 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1987 | 25 | 0.020 |
Why?
| | Schools | 1 | 2011 | 453 | 0.020 |
Why?
| | Conservation of Energy Resources | 1 | 2007 | 3 | 0.020 |
Why?
| | Behavior Therapy | 1 | 2010 | 282 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2135 | 0.020 |
Why?
| | Physical Examination | 1 | 1988 | 242 | 0.020 |
Why?
| | Calcium | 1 | 2012 | 1192 | 0.020 |
Why?
| | Radiation Monitoring | 1 | 1986 | 15 | 0.020 |
Why?
| | Massachusetts | 1 | 2006 | 174 | 0.020 |
Why?
| | Air Conditioning | 1 | 2006 | 6 | 0.020 |
Why?
| | Attitude | 1 | 1988 | 261 | 0.020 |
Why?
| | HIV | 1 | 2007 | 250 | 0.010 |
Why?
| | Medical History Taking | 1 | 1986 | 117 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2012 | 1334 | 0.010 |
Why?
| | Arousal | 1 | 2006 | 160 | 0.010 |
Why?
| | Rural Population | 2 | 1987 | 606 | 0.010 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2007 | 285 | 0.010 |
Why?
| | Physicians | 1 | 1994 | 942 | 0.010 |
Why?
| | Electronic Health Records | 1 | 2013 | 1132 | 0.010 |
Why?
| | Statistics as Topic | 1 | 1986 | 302 | 0.010 |
Why?
| | beta Carotene | 1 | 1984 | 20 | 0.010 |
Why?
| | Dementia | 1 | 1988 | 263 | 0.010 |
Why?
| | Carotenoids | 1 | 1984 | 42 | 0.010 |
Why?
| | Nitrogen Oxides | 1 | 2004 | 54 | 0.010 |
Why?
| | X-Rays | 1 | 2003 | 31 | 0.010 |
Why?
| | Pneumoconiosis | 1 | 1984 | 20 | 0.010 |
Why?
| | Heart Conduction System | 1 | 2004 | 89 | 0.010 |
Why?
| | Biophysical Phenomena | 1 | 2003 | 68 | 0.010 |
Why?
| | Population | 1 | 2003 | 32 | 0.010 |
Why?
| | Gamma Rays | 1 | 2003 | 57 | 0.010 |
Why?
| | Biophysics | 1 | 2003 | 74 | 0.010 |
Why?
| | Oxyhemoglobins | 1 | 2003 | 24 | 0.010 |
Why?
| | Databases, Factual | 1 | 2008 | 1448 | 0.010 |
Why?
| | Cell Line | 2 | 1998 | 2887 | 0.010 |
Why?
| | Mothers | 1 | 2009 | 785 | 0.010 |
Why?
| | Training Support | 1 | 2002 | 37 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1748 | 0.010 |
Why?
| | Receptors, Phospholipase A2 | 1 | 2001 | 1 | 0.010 |
Why?
| | Pharyngeal Neoplasms | 1 | 2001 | 5 | 0.010 |
Why?
| | Interleukin-3 | 1 | 2001 | 24 | 0.010 |
Why?
| | Annexin A5 | 1 | 2001 | 26 | 0.010 |
Why?
| | Vital Capacity | 1 | 2003 | 306 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1997 | 1056 | 0.010 |
Why?
| | Oxidants, Photochemical | 1 | 2001 | 8 | 0.010 |
Why?
| | Food Contamination | 1 | 2001 | 55 | 0.010 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 890 | 0.010 |
Why?
| | Lysophospholipids | 1 | 2001 | 80 | 0.010 |
Why?
| | Disease Transmission, Infectious | 1 | 2001 | 69 | 0.010 |
Why?
| | Mouth Neoplasms | 1 | 2001 | 89 | 0.010 |
Why?
| | Isoenzymes | 1 | 2001 | 302 | 0.010 |
Why?
| | Mutation | 1 | 1992 | 4015 | 0.010 |
Why?
| | Parents | 1 | 1989 | 1440 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2000 | 209 | 0.010 |
Why?
| | Fungi | 1 | 2001 | 152 | 0.010 |
Why?
| | Agriculture | 1 | 2000 | 99 | 0.010 |
Why?
| | Melanoma | 2 | 1986 | 792 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 2003 | 556 | 0.010 |
Why?
| | Reference Values | 1 | 2000 | 807 | 0.010 |
Why?
| | Ceruloplasmin | 1 | 1998 | 10 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2001 | 444 | 0.010 |
Why?
| | Fuel Oils | 1 | 1998 | 2 | 0.010 |
Why?
| | Boston | 1 | 1978 | 91 | 0.010 |
Why?
| | Histocytochemistry | 1 | 1998 | 80 | 0.010 |
Why?
| | Utah | 1 | 1998 | 67 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2000 | 811 | 0.010 |
Why?
| | Receptors, Transferrin | 1 | 1998 | 28 | 0.010 |
Why?
| | Cell Survival | 1 | 2001 | 1134 | 0.010 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1998 | 142 | 0.010 |
Why?
| | Software | 1 | 2003 | 678 | 0.010 |
Why?
| | Thiourea | 1 | 1997 | 42 | 0.010 |
Why?
| | Autoradiography | 1 | 1997 | 69 | 0.010 |
Why?
| | Blotting, Western | 1 | 2000 | 1234 | 0.010 |
Why?
| | Intubation, Intratracheal | 1 | 2000 | 288 | 0.010 |
Why?
| | Respiratory Mucosa | 1 | 2000 | 331 | 0.010 |
Why?
| | Interferons | 1 | 1998 | 195 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 1997 | 159 | 0.010 |
Why?
| | Sputum | 1 | 1978 | 313 | 0.010 |
Why?
| | Heterozygote | 1 | 1997 | 308 | 0.010 |
Why?
| | Comorbidity | 1 | 2001 | 1664 | 0.010 |
Why?
| | Epithelium | 1 | 1997 | 316 | 0.010 |
Why?
| | Interleukin-8 | 1 | 1997 | 273 | 0.010 |
Why?
| | Age of Onset | 1 | 1998 | 534 | 0.010 |
Why?
| | Heart Defects, Congenital | 1 | 2004 | 884 | 0.010 |
Why?
| | Transfection | 1 | 1998 | 943 | 0.010 |
Why?
| | Protein Binding | 1 | 2001 | 2242 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 1982 | 857 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2001 | 1487 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 1997 | 625 | 0.010 |
Why?
| | Pacific Islands | 1 | 1994 | 3 | 0.010 |
Why?
| | West Virginia | 1 | 1993 | 9 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1998 | 1243 | 0.010 |
Why?
| | Apoptosis | 1 | 2001 | 2576 | 0.010 |
Why?
| | Platelet Activating Factor | 1 | 1992 | 81 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1997 | 1250 | 0.010 |
Why?
| | Prostaglandins | 1 | 1992 | 101 | 0.010 |
Why?
| | Primary Prevention | 1 | 1994 | 202 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 1994 | 560 | 0.010 |
Why?
| | Codon | 1 | 1992 | 92 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 1992 | 158 | 0.010 |
Why?
| | DNA | 1 | 1998 | 1444 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1992 | 1094 | 0.010 |
Why?
| | Base Sequence | 1 | 1992 | 2180 | 0.000 |
Why?
| | Cognition | 1 | 1996 | 1228 | 0.000 |
Why?
| | Carcinoma, Bronchogenic | 1 | 1986 | 20 | 0.000 |
Why?
| | Eye Neoplasms | 1 | 1986 | 28 | 0.000 |
Why?
| | Carcinoma, Small Cell | 1 | 1987 | 171 | 0.000 |
Why?
| | Feasibility Studies | 1 | 1990 | 1027 | 0.000 |
Why?
| | Retinoblastoma | 1 | 1986 | 40 | 0.000 |
Why?
| | Lymphoma | 1 | 1986 | 228 | 0.000 |
Why?
| | Self Disclosure | 1 | 1984 | 65 | 0.000 |
Why?
| | Leukemia | 1 | 1986 | 244 | 0.000 |
Why?
| | Neck | 1 | 1982 | 105 | 0.000 |
Why?
| | Head | 1 | 1982 | 117 | 0.000 |
Why?
|
|
Samet's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|